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Background: Particular cytokine gene polymorphisms are involved in the regulation of the antibody production. The
consequences of already described IL-4, IL-10 and IL-13 gene polymorphisms on biological parameters and antibody
levels were investigated among 576 mothers at delivery and their newborns in the context of P. falciparum placental
malaria infection.
Methods: The study took place in the semi-rural area of Tori-Bossito, in south-west Benin, where malaria is
meso-endemic. Six biallelic polymorphisms were determined by quantitative PCR using TaqManW Pre-Designed
SNP Genotyping Assays, in IL-4 (rs2243250, rs2070874), IL-10 (rs1800896, rs1800871, rs1800872) and IL-13
(rs1800925) genes. Antibody responses directed to P. falciparum MSP-1, MSP-2, MSP-3, GLURP-R0, GLURP-R2 and
AMA-1 recombinant proteins were determined by ELISA.
Results: The maternal IL-4−590*T/IL-4+33*T haplotype (one or two copies) was associated with favorable maternal
condition at delivery (high haemoglobin levels, absence of placental parasites) and one of its component, the IL-4−590
TT genotype, was related to low IgG levels to MSP-1, MSP-2/3D7 and MSP-2/FC27. Inversely, the maternal IL-10−1082 AA
was positively associated with P. falciparum placenta infection at delivery. As a consequence, the IL-10−819*T allele
(in CT and TT genotypes) as well as the IL-10−1082*A/IL-10−819*T/IL-10−592*A haplotype (one or two copies) in which it is
included, were related to an increased risk for anaemia in newborns. The maternal IL-10−1082 AA genotype was related
to high IgG levels to MSP-2/3D7 and AMA-1 in mothers and newborns, respectively. The IL-13 gene polymorphism was
only involved in the newborn’s antibody response to AMA-1.
Conclusion: These data revealed that IL-4 and IL-10 maternal gene polymorphisms are likely to play a role in the
regulation of biological parameters in pregnant women at delivery (anaemia, P. falciparum placenta infection) and in
newborns (anaemia). Moreover, IL-4, IL-10 and IL-13 maternal gene polymorphisms were related to IgG responses to
MSP-1, MSP-2/3D7 and MSP-2/FC27 in mothers as well as to AMA-1 in newborns.
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Host susceptibility to malaria is attributable to a number
of factors, which include the genetic background of both
host and pathogen. Indeed host genetic factors are in-
volved in the regulation of the individual’s immunological
competence. Several chromosomal regions containing
genes coding for cytokines or cytokine receptors have
been implicated in the control of P. falciparum infection
levels [1-3]. The 5q31-q33 region located in chromosome
5 notably contains a number of genes initially found asso-
ciated with the immune response directed to Schistosoma
haematobium [4]. In the case of malaria, studies have pro-
vided evidence for linkage between the 5q31-q33 region
and blood infection levels in populations originating from
Burkina Faso [5], Cameroon [6] and Senegal [7]. Interleu-
kin (IL) genes such as IL-3, IL-4, IL-5, IL-9 and IL-13 are
notably clustered in this chromosome region [5,8].
The products of the pleiotropic IL-4 gene intervene in
multiple immune modulating functions depending on a
variety of cell types [9]. IL-4 is defined as a cytokine pro-
duced by Th2 cells, and is involved in the regulation of
the humoral immune response. It is a key factor for the
differentiation of precursor T helper cells into Th2 cells
that induce IgE production by plasmocytes. This cyto-
kine is an important regulator in the isotype switching
from IgM/IgG to IgE [10]. Finally, IL-4 plays a critical
role in the regulation of the antibody response induced
by Plasmodium parasites [8,11]. A gene located in the
1q32.1 region of chromosome 1 encodes IL-10 which
synergizes the production of antibody isotypes (IgG, IgA
and IgM) induced by IL-4 [12]. IL-4 and IL-10 have been
shown to be important for parasite clearance in later
antibody-mediated phases of infection [13]. Among the
genes located in the 5q31.1 region, IL-13 encodes a cyto-
kine which is a central mediator of the physiological
changes induced by allergic inflammation. The functions
of IL-13 considerably overlap those of IL-4, especially
with regard to their role on erythropoiesis. IL-13 has
anti-inflammatory properties and induces IgE secretion
from activated human B cells [14].
Several polymorphisms affecting IL-4, IL-10, IL-13 genes,
lead to changes in cytokine production levels that may im-
pact isotype switching as well as cell interaction and thus
be associated with immune-related diseases such as malaria
[15,16]. A variant at position IL-4−590 C/T has been shown
to enhance IL-4 and IgE production [17]. Studies in
Burkina Faso [18] and Mali [19,20] revealed differences in
the distribution of IL-4−590 C/T allele and genotype fre-
quencies between Fulani and non Fulani ethnic groups. In
both studies, the IL-4−590*T allele was associated with high
levels of anti-malaria IgG levels among Fulani. A study
conducted among Ghanaian children showed that carriers
of both IL-4−590*T and IL-4+33*T alleles presenting cerebral
malaria had elevated IgE compared to non carriers [21].There is evidence for associations between IL-10 gene
polymorphisms grouped into haplotypes and IL-10 levels
as well as antibody levels. The IL-10−1082G/A polymorph-
ism has notably been associated with variable IL-10 pro-
duction [22]. The IL-10−592*A allele has been linked to low
levels of total IgE and the IL-10−1082*A/IL-10−592*A haplo-
type has been negatively associated with specific IgE and
IgG4 [23]. IL-10−819*C was associated with skin lesions in-
duced by leishmaniasis, in relation with high IL-10 levels
produced by carriers of the IL-10−819 CC genotype [24].
Besides, low IL-10 producing IL-10−1082*A/IL-10−819*T/IL-
10−592*A haplotype carriers may be at risk of severe malar-
ial anaemia, among pediatric populations [25]. Finally, the
IL-13−1055*T allele is found in individuals who present en-
hanced IL-13 production and seem protected against se-
vere malaria [16].
In endemic areas, children aged less than 5 years are
particularly affected by malaria because of their lack of
specific acquired immunity. Several authors have reported
that the susceptibility of the child aged less than one year
is linked to malaria infections during pregnancy. Thus
children born from mothers with a P. falciparum infected
placenta at delivery have an increased risk of developing
malaria during their first years of life [26-28]. Despite this
information, knowledge on the genetic and immunological
mechanisms related to increased susceptibility of pregnant
women and their children to malaria is still lacking. We
hypothesized that if specific maternal cytokine gene poly-
morphisms lead to an increased production of specific
antimalarial antibodies at the individual level, they may
also help to lower the in utero sensitization of the fetus to
plasmodial antigens, and therefore contribute to delay the
appearance of the first malaria attacks during the first
months of life.
Studies conducted in different malaria endemic areas
have reported that IgG to various malaria antigens were
associated with clinical protection [29-31]. Passive anti-
body transfer to non-immune individuals showed that
protective immunity among adults in endemic areas is at
least partly humoral [32]. Cytophilic antibodies to merozo-
ite surface protein-3 (MSP-3) and glutamate-rich protein
(GLURP) were shown to be predominant in protected in-
dividuals, contrary to non-cytophilic antibodies [33]. Stud-
ies have also shown that antibodies directed to MSP-1−19
and apical membrane antigen 1 (AMA-1) were associated
with a reduced risk of clinical malaria [34]. Antibodies to
AMA-1 have been reported to exhibit parasite growth
inhibitory activity in a growth inhibition assay [35].
Antibodies to merozoite surface protein-2 (MSP-2) of
P. falciparum have been associated with protection from
clinical malaria in independent studies [36]. Each of these
antigens (AMA-1, MSP-119, MSP-2, MSP-3, and GLURP)
is considered as a candidate for inclusion into a multiva-
lent malaria vaccine.
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quences of known cytokine gene polymorphisms on ma-
ternal biological parameters and specific antibody levels at
delivery and to investigate their role on fetal health and
immunity, taking into account the presence or absence of
placental infection by P. falciparum. The simultaneous
measurement of the antibody response directed against a
panel of plasmodial antigens will allow drawing a picture
of the specific immune status at the individual level.Methods
Study area
The study was conducted in the rural area of Tori-Bossito,
(45,000 inhabitants, 40 km west of Cotonou, Benin).
Malaria transmission is perennial, with two seasonal peaks
corresponding to rainy seasons, from April to July and
September to November. P. falciparum is the main cause
of infection and an average entomological inoculation rate
(EIR) of 15.5 infective bites per person per year has been
measured [37].
Study population and sampling
A cohort of 660 mothers and their children was constituted
from June 2007 to June 2008 in three maternities from the
Tori-Bossito area, welcoming parturient women from nine
surrounding villages [37]. In the present study, 576 mothers
and their newborns were investigated, excluding twins and
children who died before D7. At delivery, peripheral blood
was drawn from all mothers and cords in EDTA
VacutainerW tubes (Becton Dickinson, Meylan, France).
Plasma cytokine levels were measured from blood collected
for 80 mothers and cords in supplementary heparinized
VacutainerW tubes. After collection, plasma samples were
stored at −80°C and buffy-coats at −20°C.
Thick blood smears were prepared from circulating
blood of mothers, cord blood and placenta samples. Stain-
ing with Giemsa allowed determining P. falciparum para-
sitaemia by microscopy. Leukocytes and parasites were
counted simultaneously until leukocyte or parasite num-
bers reached 500. A thick blood smear was declared nega-
tive if no parasite was found after 500 leucocytes had been
counted. The following variables were measured for each
mother: (1) village of residence; (2) age; (3) parity and (4)
estimated exposure to malaria transmission during preg-
nancy assessed by means of mosquito catches precisely de-
scribed in Cottrell et al. [38]; (5) circulating parasite
density and (6) presence of placental parasites at delivery.
Biological assays were assessed in part in the labora-
tory established at Cotonou by the UMR 216 in partner-
ship with the Faculté des Sciences de la Santé (FSS) and
the Institut des Sciences Biomédicales Appliquées
(ISBA) in Benin, and in the laboratory of the UMR 216
in Paris, France. For each included parturient woman, awritten informed consent was obtained. Both the Ethical
Committee of the FSS in Benin and the Consultative
Committee on Professional Conduct and Ethics (CCDE)
of the Institut de Recherche pour le Développement
(IRD) approved the protocol.Human genotyping
Genomic DNA was extracted from maternal buffy-coats
containing mononuclear cells, using QiampW DNA blood
midi kits according to the manufacturer’s instructions. Six
cytokine gene polymorphisms were determined by quanti-
tative PCR using TaqManW Pre-Designed SNP (Single Nu-
cleotide Polymorphism) Genotyping Assays, including the
C/T mutation located at the −590 (rs2243250,) and +33
(rs2070874) positions of the IL-4 gene, the G/A mutation
at the −1082 (rs1800896), the C/T mutation at the −819
(rs1800871) and the C/A mutation at the −592
(rs1800872) positions of the IL-10 gene, and the C/T mu-
tation at the −1055 position (rs1800925) of the IL-13 gene.
Each TaqMan genotyping assay contained two primers for
amplifying the sequence of interest and two TaqManW
MGB probes for detecting alleles. The presence of two
probe pairs in each reaction allowed genotyping of the
two possible variant alleles at the SNP site in the DNA tar-
get sequence. The genotyping assay determined the pres-
ence or absence of a SNP based on the change in
fluorescence of the dyes associated with the probes. Amp-
lification of each locus was performed in a total volume of
10 μl, containing 0.25 μM of each primer, 2 μl genomic
DNA and 2× PCR Master Mix (Applied Biosystems mas-
ter mix contains AmpliTaq GoldW DNA Polymerase, Ultra
Pure water, deoxyribonucleotide triphosphates (dNTPs),
ROX™ Passive Reference and Buffer components) in a
programmable thermocycler (Applied Biosystems PRISM
7900HTW).Malaria antigens
Seven recombinant proteins corresponding to antigens of
P. falciparum expressed on the surface of merozoites and
candidates for inclusion in a multivalent asexual stage vac-
cine [39] were chosen. The recombinant proteins were
obtained free of charge through an international network
of collaborators. MSP-119 (Uganda-Palo-Alto strain) (gift
from Pasteur Institute, Paris, France) was expressed in a
Baculovirus/insect cell system [40]; AMA-1 25–545 (FVO
strain) (gift from the Biomedical Primate Research Centre,
Rijswijk, The Netherlands) was expressed in Pichia
pastoris [41]; MSP-2/3D7 and MSP-2/FC27 (gift from La
Trobe University, Melbourne, Australia) [42] as well as
MSP-3 212–380 (F32 strain) [43], GLURP 25–514 (F32 strain)
and GLURP 706–1178 (F32 strain) [44] (all from the Statens
Serum Institute, Copenhagen, Denmark) were expressed
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(amino acids 706–1178) corresponded to the N-terminal
nonrepeat region and to the C-terminal repeat region of
the protein, respectively [30].Antibody measurements
An Enzyme-Linked Immuno-Sorbent Assay (ELISA) fol-
lowing a standardized methodology described in the Afro-
immunoassay network standard operating procedure (pro-
cedures AIA-001-01 and −02) was used to assess the anti-
body response directed to the panel of P. falciparum
recombinant proteins.
ELISA plates were coated overnight with 100 μl of
recombinant protein solutions at a final concentration of
1 μg/ml in 1X PBS. Blocking buffer (3% milk powder in
PBS - 0.1% Tween 20) was added (150 μl per well) and
plates were kept at room temperature for 1 hour. Plasma
samples were diluted in 1X PBS - 1% milk powder -
0.1% Tween 20-0.02% sodium azide. For IgG measure-
ments, maternal and cord plasma samples were diluted
1:200 for all recombinant proteins except for AMA-1
where a dilution 1:2000 was used. For IgM measure-
ments, plasma samples from maternal blood were di-
luted 1:200 and those of cord blood 1:50.
Two polyclonal antibodies conjugated to HRP were used:
a goat anti-human IgG (Caltag H10007) and a goat anti-
human IgM (Caltag H15007) both diluted 1: 3000. Bound
enzyme was detected with TMB and the reaction was
stopped with 0.2 M H2SO4 (100 μl/well). Plates were ex-
tensively washed between each incubation period with 1X
PBS - 0.1% Tween 20-0.5 M NaCl. The optical density
(OD) was read at 450 nm (reference filter 620 nm).
Positive-control plasma samples from Gabonese individuals
and negative-control plasma samples from Dutch individ-
uals were included in each plate. A Microsoft Excel based
curve fitting program (ADAMSEL FPL b039) containing a
collection of macros and worksheets was used for calculat-
ing antibody concentrations (μg/ml) from the OD values,
using the standard curves obtained from each ELISA test
plate (http://www.emvda.bio.ed.ac.uk/software.php).Cytokine assays
IL-4, IL-10 and IL-13 plasma levels were measured in a
sub-sample of 80 mothers presenting no difference in
any criterion compared to the whole group of 576
mothers. Four of them presented P. falciparum parasites
both in circulating blood and placenta. The DuoSetW
ELISA tests (R&D systems) were used and results were
expressed in pg/ml by reference to standard curves pre-
pared in each plate with recombinant cytokines. Thresh-
olds of sensitivity were 31 pg/ml for IL-4 and IL-10, and
94 pg/ml for IL-13.Statistical analysis
The significance of deviation from Hardy-Weinberg
equilibrium was tested using the χ2 goodness-of-fit test.
Strength of linkage disequilibrium (LD) between pairs of
markers located along a same chromosome was mea-
sured as r2 [45], using the Haploview software v4.1 [46].
Regions of strongly associated markers (LD blocks) were
inferred using the confidence-interval method proposed
by Gabriel et al. [47]. For SNPs located within a same
LD block, haplotypes were inferred from the unphased
genotype data using the Bayesian method implemented in
PHASE v.2.1.1 [48], using default parameters. To avoid the
convergence of the algorithm to a local maximum, we ran
it 10 times with different random seeds and kept the output
from the run with the best average value. The most prob-
able haplotype constitution of each sample was also in-
ferred with a maximum likelihood method using the
Expectation-Maximization (EM) algorithm implemented in
Arlequin v3.1 [49]. All samples had the same pair of haplo-
types estimated by the EM and PHASE methods, therefore
ensuring the reliability of the inference procedure.
For univariate analyses, differences in proportions were
analyzed using the Chi square test. Differences in means
were tested by the nonparametric Mann–Whitney U-test
or Kruskal-Wallis test (for more than 2 groups to be com-
pared). Statview 5.0 (SAS Institute Inc., Cary, NC) was
used for these calculations. Results of the univariate ana-
lyses involving maternal cytokine gene polymorphisms are
reported in the Additional files 1 and 2 (for biological pa-
rameters of either the mothers or the newborns) and in
the Additional files 3 and 4 (for P. falciparum specific
antibody levels of either the mothers or the newborns).
Variables with P values < 0.20, were further considered in
the multivariate analysis.
Multivariate analysis of the association between anaemia,
placental infection and covariates was performed using
multiple logistic regressions. For haemoglobin level, multi-
variate analyses were conducted using multiple linear re-
gressions. Concerning antibody levels, due to non Gaussian
distribution (even when data were log-transformed), me-
dian regression models were used. These models estimate
standard errors via bootstrapping. We specified 1,000 repli-
cations for each analysis, and when significant (P < 0.05) a
new analysis under the same model was carried out using
5,000 replications. Associations between biological and im-
munological phenotypes and each cytokine gene poly-
morphism were tested under additive, dominant and
recessive genetic models.
The four tables reporting results of association, listed
only cytokine gene polymorphisms for which multivari-
ate analysis concluded to significant differences in rela-
tion to mothers and/or newborns biological and/or
immunological parameters. For all tests, P values of less
than 0.05 were considered significant. All analyses were
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LP, College Station, TX, USA).
Results
Study population, clinical and parasitological
characteristics
Haematological and parasitological data of the 576 in-
cluded mothers and their newborns are presented in
Table 1. Mothers distributed into 88 primigravidae (15%,
mean age = 25.0 years) and 488 multigravidae (85%,
mean age = 27.8 years). Primigravidae were more nu-
merous than multigravidae to present circulating para-
sites at delivery (15 (17.0%) vs. 34 (7.0%), P = 0.002) but
parasite densities did not differ (median parasite density/
μl (IQR): 27 (5–514) vs. 5 (2–77), P = 0.08). Among the
563 mothers for whom placenta blood smears were
available, 63 (10.9%) mothers presented a P. falciparum
infected placenta at delivery. More positive smears were
identified in primigravidae compared to multigravidae
(17 (19.8%) vs. 46 (9.6%), P = 0.006). Anaemia was fre-
quent, with 39.1% and 61.5% of mothers and newborns
presenting haemoglobin values < 11 g/dl and < 15 g/dl,
respectively. The mean birth weight (± SD) was 2985 g
(± 388 g) with 53 newborns (9.2%) presenting a low
birth weight (< 2500 g). The 5 newborns presenting par-
asites in cord blood were born of mothers with both cir-
culating P. falciparum at delivery and presence of
placental malaria infection.
Maternal IL-4, IL-10 and IL-13 gene polymorphisms
Cytokine gene polymorphisms were determined for the
whole group of 576 mothers. No statistically significant
deviation from Hardy-Weinberg equilibrium was ob-
served for any polymorphism (all P-values > 0.44,
Table 2). The heterozygous carriage was predominant
(at least 50%), except for IL-4−590 and IL-10−1082. Since
the IL-13−1055 SNP presented virtually no LD with the
two IL-4 SNPs in position −590 and +33 along theTable 1 Haematological and parasitological data among
576 mothers and their newborns
Parameters Mothers
(peripheral blood)
Newborns
(cord blood)
Haemoglobin (g/dl) 11.3 (± 1.5) 14.5 (± 2.0)
mean (± SD) a
Anaemia 224 (39.1) 351 (61.5)
n (%) b
P. falciparum prevalence 49 (8.5) 5 (0.9)
n (%) c
Parasite density d 556 (159–9990) 367 (235–1492)
a 3 (5) missing values for mothers (newborns).
b anaemia defined as Hb < 11 g/dl (mothers) and Hb < 15 g/dl (newborns).
c 2 missing values.
d median parasite density (/μl) (25th-75th percentiles), zero values excluded.chromosome 5 (r2 = 0.03 with both SNPs, Figure 1),
only haplotypes including the two IL-4 SNPs were
reconstructed and the IL-13 SNP was treated independ-
ently in statistical analyses. By contrast, the three
IL-10 SNPs located on chromosome 1 belong to a single
block of LD (Figure 1) and were thus combined into
haplotypes. On the basis of literature data, the particular
IL-4−590*T/IL-4+33*T and IL-10−1082*A/IL-10−819*T/IL-10
−592*A haplotypes were selected, in order to examine
their relationships with biological and immunological
parameters. This allowed to consider three groups of
mothers bearing either two copies (n = 140), one copy
(n = 291) or no copy (n = 145) of IL-4−590*T/IL-4+33*T
haplotype (referred to as IL4-TT haplotype). Similarly,
three groups of mothers were defined, who carried either
two copies (n = 87), one copy (n = 293) or no copy (n =
196) of IL-10−1082*A/IL-10−819*T/IL-10−592*A haplotype (re-
ferred to as IL10-ATA haplotype).
Genotype-dependent plasma levels of cytokines are
presented in Figure 2 in a sub-sample of 80 mothers,
where it appears that similar IL-4, IL-10 or IL-13 levels
were secreted in the plasma of mothers harboring each
of the three genotypes of the corresponding cytokine
gene polymorphisms, except for IL-10−1082, for which
mothers with the GA genotype presented lower IL-10
plasma levels than their counterparts with the GG geno-
type (P = 0.006). But this difference did not impact the
cytokine levels among the different IL-4 and IL-10
haplotype groups, as illustrated in Figure 3.
Association between maternal cytokine gene
polymorphisms and biological data of mothers
Maternal haemoglobin levels at delivery were impacted
by IL-4 gene polymorphisms (Table 3, on the basis of
the results of the univariate analysis presented in the
Additional file 1). Indeed, presence of the IL-4+33*T allele
in genotypes CT and TT was associated with higher
haemoglobin levels than those found in mothers carry-
ing the CC genotype (P = 0.03). This observation was
reinforced when examining the association of the IL4-
TT haplotype under a dominant effect (P = 0.03). The
same associations remain valid when considering mater-
nal anaemia, defined by an Hb level < 11 g/dl, where it
appeared that IL-4+33 CT and TT carriers as well as car-
riers of one or two copies of IL4-TT haplotype were less
at risk of anaemia than IL-4+33 CC and non IL4-TT car-
riers, respectively (both analyses, OR = 0.66, P = 0.04).
Village localization, young mother’s age, primigravidity
and IL-4 gene polymorphisms were associated with pla-
cental malaria infection under a dominant model (Table 3).
Indeed, mothers harboring either the IL-4−590*T allele in
genotypes CT and TT or the IL-4+33*T allele in genotypes
CT and TT were less numerous to present placental malaria
infection at delivery than mothers with CC genotype
Figure 1 Patterns of linkage disequilibrium between IL-10 SNPs
and between IL-4 and IL-13 SNPs. High pairwise LD (r2) between
markers is illustrated with dark shading. The r2 values (× 100) for the
marker pairs are listed in the corresponding boxes.
Table 2 Distribution of cytokine gene polymorphisms in the study population of 576 mothers
Gene SNPs Location in
the gene
Genotype Frequency in the
study population
Hardy-Weinberg equilibrium test
χ 2 (P-value, df = 2)
IL-4 rs2243250 −590 C/T CC 25 (4%) χ 2 = 0.03 (P = 0.98)
CT 193 (34%)
TT 358 (62%)
rs2070874 +33 C/T CC 145 (25%) χ 2 = 0.08 (P = 0.96)
CT 290 (50%)
TT 141 (25%)
IL-10 rs1800896 −1082 G/A GG 47 (8%) χ 2 = 0.63 (P = 0.73)
GA 223 (39%)
AA 306 (53%)
rs1800871 a −819 C/T CC 184 (33%) χ 2 = 1.09 (P = 0.58)
CT 281 (51%)
TT 90 (16%)
rs1800872 −592 C/A CC 191 (33%) χ 2 = 1.64 (P = 0.44)
CA 294 (51%)
AA 91 (16%)
IL-13 rs1800925 −1055 C/T CC 186 (32%) χ 2 = 1.48 (P = 0.48)
CT 295 (51%)
TT 95 (17%)
a 21 missing values.
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The same pattern was observed for the IL4-TT haplotype: a
lesser prevalence of placental malaria infection was con-
firmed in mothers carrying one or two copies of the IL4-TT
haplotype when compared to non IL4-TT haplotype car-
riers (OR = 0.54, P = 0.03).
Village localization, primigravidity and IL-10−1082 poly-
morphism were associated with placental malaria infec-
tion under a recessive model, with more IL-10−1082 AA
mothers presenting placental malaria infection at deliv-
ery in comparison to IL-10−1082 GG and GA mothers
(OR = 1.95 P = 0.02) (Table 3). Due to the strong correl-
ation between circulating parasite densities and prevalence
of placental infection at delivery, maternal age, village,
primigravidity and the same IL-10−1082 AA genotype were
positively associated under a recessive model with the
level of circulating parasite densities (OR [CI95] = 2.34
[1.23-4.48], P = 0.01).
Association between maternal cytokine gene
polymorphisms and biological data of newborns
Newborn’s anaemia, defined by an Hb level < 15 g/dl, but
not cord haemoglobin levels considered as a continuous
variable, was impacted by IL-10 gene polymorphisms
(Table 4, on the basis of the results of the univariate analysis
presented in the Additional file 2). Indeed, maternal
anaemia, young maternal age and IL-10−819 polymorphism
were associated with newborn’s anaemia under a dominantmodel: the presence of the IL-10−819*T allele in the CT and
TT genotypes was related to a higher risk of newborn’s an-
aemia compared to its absence in CC carriers (OR = 1.46,
P = 0.04). Combined to a borderline effect towards a higher
risk of anaemia in infants born to IL-10−1082 GA and AA
mothers compared to GG ones (OR = 1.81, P = 0.06),
this effect persisted in infants issued from mothers
Figure 2 Plasma levels of cytokines according to cytokine genotypes, in 80 mothers at delivery. a 5 missing values. Boxes delimit median
values and bars denote the 25th and 75th percentiles. Differences in cytokine levels between genotypes were examined for each cytokine variant
with the Mann–Whitney U test.
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pared to mothers without the IL10-ATA haplotype (OR =
1.45, P = 0.04).
Birthweight, either considered as a continuous variable
or dichotomized into less or more than 2500 g, was not
influenced by the maternal cytokine gene polymor-
phisms under study.
Association between maternal cytokine gene
polymorphisms and antibody responses of mothers
IgG levels to the seven P. falciparum recombinant pro-
teins under investigation are illustrated in Figure 4, as wellFigure 3 Plasma levels of cytokines according to cytokine haplotypes
denote the 25th and 75th percentiles. Differences in cytokine levels betweeas IgM to AMA-1. In all cases, specific antibody levels
were higher in the circulating blood of mothers at delivery
than in the cord blood of their newborns (all P < 0.02).
The AMA-1 recombinant protein elicited the highest anti-
body levels in both mother and child groups.
MSP-1, MSP-2/3D7 and MSP-2/FC27 were the only an-
tigens for which specific antibody responses of mothers
were clearly associated with cytokine gene polymorphisms
(Table 5 on the basis of the results of the univariate ana-
lysis presented in the Additional file 3). More precisely,
IL-4−590 TT carriers presented lower IgG levels to MSP-1
(P = 0.02) and MSP-2/3D7 (P = 0.03) than mothers with, in 80 mothers at delivery. Boxes delimit median values and bars
n haplotypes were examined with the Kruskal-Wallis test.
Table 3 Association between maternal cytokine gene polymorphisms and mothers’ biological parameters: multivariate
analysis
Maternal cytokine gene (n) Haemoglobin
(g/dl) (SD) a
P b Anaemia
OR [CI95]
c
P b P. falciparum placenta
infection OR [CI95]
d
P e
IL-4−590 genotypes:
CC (25) 11.2 (0.3) 1
CT (193) 11.1 (0.3) 0.88 1.13 [0.48-2.65] 0.77
TT (358) 11.3 (0.3) 0.65 0.87 [0.38-1.98] 0.73 OR CT and TT vs. CC =
0.36 [0.14-0.93]
0.03
IL-4+33 genotypes:
CC (145) 11.3 (0.2)
CT and TT (431) 11.6 (0.1) 0.03 OR CT and TT vs. CC =
0.66 [0.44-0.97]
0.04 OR CT and TT vs. CC =
0.54 [0.31-0.94]
0.03
IL-4−590/IL-4+33 haplotypes:
No IL4-TT (145) 11.3 (0.2)
1 or 2 copies IL4-TT (431) 11.6 (0.1) 0.03 OR 1 or 2 copies IL4-TT vs. no IL4-TT =
0.66 [0.44-0.97]
0.04 OR 1 or 2 copies IL4-TT vs. no IL4-TT =
0.54 [0.31-0.94]
0.03
IL-10−1082 genotypes:
GG (47) 11.4 (0.2) 1
GA (223) 11.3 (0.2) 0.53 1.01 [0.52-1.94] 0.98
AA (306) 11.3 (0.2) 0.59 1.23 [0.65-2.34] 0.52 OR AA vs GG and GA =
1.95 [1.11-3.42]
0.02
a 3 missing values.
b analysis adjusted on village.
c anaemia defined as Hb < 11 g/dl.
d 13 missing values.
e analysis adjusted on parity and village.
P values < 0.05 are in bold.
Table 4 Association between maternal cytokine gene polymorphisms and newborns’ biological parameters:
multivariate analysis
Maternal cytokine gene (n) Haemoglobin (g/dl) (SD) a P b Anaemia OR [CI95]
c P d
IL-10−1082 genotypes:
GG (47) 15.1 (0.3)
GA and AA (529) 14.6 (0.3) 0.07 OR GA and AA vs GG = 1.81 [0.98-3.32] 0.06
IL-10−819 genotypes:
CC (191) 14.8 (0.2)
CT and TT (385) 14.6 (0.2) 0.14 OR CT and TT vs CC = 1.46 [1.02-2.10] 0.04
IL-10−592 genotypes:
CC (191) 14.7 (0.1)
CA and AA (385) 14.4 (0.2) 0.13 OR CA and AA vs CC = 1.36 [0.95-1.95] 0.09
IL-10−1082/IL-10−819/IL-10−592 haplotypes:
No IL10-ATA (196) 14.8 (0.2)
1 or 2 copies IL10-ATA (380) 14.6 (0.2) 0.13 OR 1 or 2 copies IL10-ATA vs. no IL10-ATA = 1.45 [1.02-2.08] 0.04
a 5 missing values.
b analysis adjusted on maternal anaemia (Hb < 11 g/dl) and low birthweight (< 2500 g).
c newborn’s anaemia defined as Hb < 15 g/dl.
d analysis adjusted on maternal anaemia and age.
P values < 0.05 are in bold.
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Figure 4 Antibody levels to P. falciparum recombinant proteins in 576 mothers at delivery and their newborns. Boxes delimit median
values and bars denote the 25th and 75th percentiles. Asterisks (*) indicate that mothers have higher antibody levels than their newborns (Mann
Whitney U-test, all P < 0.02) Symbols used for bars: mothers (grey) and infants (white).
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was related to the antibody response to MSP-2/FC27
under an additive model, with decreasing IgG levels from
mothers bearing CC to CT and TT genotypes (P = 0.02).
Finally, IgG levels to MSP-2/3D7 were higher for mothers
with the IL-10−1082 AA genotype than for those with GG
and GA genotypes (P = 0.04).
Association between maternal cytokine gene
polymorphisms and antibody responses of newborns
Only cord blood IgG levels directed to AMA-1 were
impacted by maternal cytokine gene polymorphisms
(Table 6, on the basis of the results of the univariate ana-
lysis presented in the Additional file 4). Namely, an asso-
ciation involved IgG levels to AMA-1 and IL-10−1082
under a recessive effect, with higher IgG levels in
newborns from IL-10−1082 AA vs. GG and GA mothers
(P = 0.04). In contrast, maternal IL-13−1055 was associ-
ated with lower IgG levels to AMA-1 under a recessive
effect, concerning newborns from IL-13−1055 TT vs. CC
and CT mothers (P = 0.03).
Discussion
The present study aimed at exploring the impact of ma-
ternal cytokine gene polymorphisms on biological pa-
rameters and antimalarial antibody responses of mothers
at delivery and their newborns. Cytokines involved in
antibody production such as IL-4, IL-10 and IL-13 were
investigated. A clear impact of IL-4 gene polymorphisms
on biological parameters of mothers at delivery was re-
vealed. Indeed, the IL4-TT haplotype (one or two copies)was found negatively associated with P. falciparum pla-
centa infection and maternal anaemia. The IL-4−590 TT
genotype was related to lower maternal IgG levels to
MSP-1, MSP-2/3D7 and MSP-2/FC27 than the CC and
CT genotypes. The maternal IL-4 gene polymorphism
did impact neither biological parameters nor antibody
responses of the newborns. IL-10−1082 AA genotypes
were positively associated with both P. falciparum pla-
centa infection and circulating parasites in mothers.
Similarly, IL-10−819 CT and TT genotypes as well as the
IL10-ATA haplotype (one or two copies) were positively
related to anaemia in newborns. Concerning antibody
responses, IL-10−1082 AA genotypes were associated with
higher IgG levels to MSP-2/3D7 and AMA-1 in mothers
and in newborns, respectively. The only association in-
volving IL-13−1055 concerned the IgG response to AMA-
1 in cord blood, with lower levels in newborns from
mothers with the TT vs. CC and CT genotypes. IL-4 and
IL-10 haplotypes were not related to plasma cytokine
levels, probably due to the small sample size of the sub-
population in which cytokine levels were measured.
Around 40% of the mothers and more than 60% of the
newborns presented anaemia. The relationships between
anaemia during pregnancy and birth outcomes were
studied in depth in this cohort by Koura et al., who no-
ticed that these prevalence rates were in agreement with
those already recorded in Benin, and observed that new-
born’s anaemia was related to maternal anaemia [50].
Our finding of a lower prevalence of placental malaria
infection in mothers with either the IL-4−590 or IL-4+33
CT and TT genotypes, or still the IL4-TT haplotype, is in
Table 5 Association between maternal cytokine gene
polymorphisms and antibody levels to P. falciparum
antigens in mothers: multivariate analysis
Antibody
response
Maternal cytokine
gene (n)
Antibody levels
(μg/ml) a (SD)
P
IgM to AMA-1
IL-10−1082 genotypes:
GG (47) 13.9 (3.3)
GA (223) 17.0 (3.5) 0.08 b
AA (306) 20.0 (3.7)
IgG to MSP-1
IL-4−590 genotypes:
CC and CT (218) 49.0 (5.5)
TT (358) 32.8 (7.0) 0.02 c
IgG to MSP-2/3D7
IL-4−590 genotypes:
CC and CT (218) 95.5 (10.3)
TT (358) 70.3 (11.9) 0.03 d
IL-10−1082 genotypes:
GG and GA (270) 68.2 (6.2)
AA (306) 92.9 (12.2) 0.04 d
IgG to MSP-2/FC27 IL-4−590 genotypes:
CC (25) 147.7 (61.7)
CT (193) 98.0 (62.7)
TT (358) 85.4 (62.8) 0.02 b
IgG to GLURP-R2 e
IL-4−590 genotypes:
CC (25) 23.2 (6.9)
CT and TT (551) 38.3 (7.6) 0.05 d
IL-10−1082/IL-10−819/
IL-10−592 haplotypes:
No or 1 copy
IL10-ATA (489)
38.6 (3.0)
2 copies IL10-ATA (87) 24.6 (7.6) 0.07 d
a median value.
b analysis adjusted on village.
c analysis adjusted on presence of P. falciparum circulating parasites in
mothers and presence of placental parasites.
d analysis adjusted on presence of placental parasites.
e 5 missing values.
P values < 0.05 are in bold.
Table 6 Association between maternal cytokine gene
polymorphisms and antibody levels to P. falciparum
antigens in newborns: multivariate analysis
Antibody
response
Maternal
cytokine gene (n)
Antibody levels
(μg/ml) a (SD)
P
IgG to AMA-1
IL-10−1082 genotypes:
GG and GA (270) 1497.3 (214.0)
AA (306) 1638.9 (68.3) 0.04 b
IL-13−1055 genotypes:
CC and CT (481) 1596.0 (230.8)
TT (95) 1444.0 (69.9) 0.03 b
IgG to MSP-2/3D7
IL-10−1082 genotypes:
GG and GA (270) 46.0 (4.1)
AA (306) 57.6 (6.5) 0.08 c
IgG to GLURP-R0
IL-10−592 genotypes:
CC and CA (485) 3.2 (0.3)
AA (91) 2.2 (0.5) 0.06 c
IL-10−1082/IL-10−819/
IL-10−592 haplotypes:
No or 1 copy
IL10-ATA (489)
3.2 (0.3)
2 copies IL10-ATA (87) 2.2 (0.5) 0.05 c
a median value.
b analysis adjusted on maternal age, parity and estimated exposure to malaria
transmission during pregnancy.
c analysis adjusted on presence of P. falciparum circulating parasites
in mothers.
P values < 0.05 are in bold.
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aria risk in IL4-TT carriers from Indian tribal popula-
tions [51]. On the contrary, the IL-4−590*T allele was
related to high prevalence of P. falciparum infection in
asymptomatic Fulani of Mali, but not in a sympatric
group of Dogon [19]. The lesser prevalence of placental
parasites in mothers carrying one or two copies of the
IL4-TT haplotype was consistent with the higher haemo-
globin values (and decreased risk of anaemia) observed
in these mothers at delivery, probably due to a lesserimpact of malaria-induced anaemia. A complementary
explanation would be that IL-4 is known for its role in
the promotion of erythropoiesis [52]. It would be coher-
ent that these favorable maternal condition should be
accompanied by strong antimalarial antibody responses,
as it has been already demonstrated for specific IgG in
Fulani individuals with the IL-4−590*T allele [18]. This
would be in agreement with a previous observation
made in malaria-infected individuals, of an association
between the activation of IL-4 producing T-cell subsets
and the production of antimalarial specific antibodies
[11]. Those antibodies would reflect an effective re-
sponse to infecting parasites [53], allowing to combat in-
fection and therefore to prevent its evolution toward
high parasite densities and sequestration into the pla-
centa. Nonetheless, in the present study, the IL-4−590 TT
genotype was uniformly associated negatively with ma-
ternal IgG levels to MSP-1, MSP-2/3D7 and MSP-2/
FC27. The most obvious hypothesis for this observation
rests on a decreased induction of antimalarial antibodies
in IL-4−590 TT mothers as a result of a lighter weight of
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should be reminded that the Beninese women under
study cumulated previous malaria experience, and/or
that co-infection with other parasitic or bacterial patho-
gens not investigated in the present study may have oc-
curred, thereby preventing a clear relationship. Some
regulatory factors placed under genetic control and in
LD with IL-4 gene polymorphisms may also impact the
data [54]. In fact, studies on the relationships between
IL-4 gene polymorphisms and IgG levels are limited and
conflicting [18,55]. The Th2 cytokine induces Ig class
switching from IgM/IgG to IgE [9,10]. IL-4 has been in-
criminated in the aggravation of cerebral malaria due to
its role in an increase in parasite mass [56], in an infil-
tration by monocytes, basophils, and eosinophils and an
increase in parasite sequestration [57]. In the context of
our study, independently of any morbidity linked to mal-
aria, no biological or immunological advantage could be
deduced for the newborns from the IL-4 genetic charac-
teristics of their respective mothers. Comparatively to
IgG which are mainly of maternal origin in the cord
blood due to the existence of a passive transfer of anti-
bodies during the pregnancy, IgM do not cross the pla-
centa and are therefore synthesized by the fetus, as a
result of a sensitization to malaria antigens in utero
[58,59]. Nevertheless, the low levels and prevalence rates
of newborns’ IgM to AMA-1 hampered any observation
in link with maternal cytokine gene polymorphisms.
As for IL-4, data from the literature indicate that IL-10
gene polymorphisms need to be analyzed combined into
haplotypes and no longer at the limiting scale of single nu-
cleotide polymorphisms. We thus studied the effects of the
candidate IL-10−1082 G/A, IL-10−819 C/T and IL-10−592 C/A
polymorphisms simultaneously, through a haplotype ana-
lysis, in relation to the biological and immunological data
recorded in both the mothers and their newborns. As for
IL-4, were only considered the final results issued from a
multivariate analysis taking into account specific maternal
parameters such as age, parity, residence place, the esti-
mated entomological inoculation rate during the whole
pregnancy period and/or the presence of circulating para-
sites as well as placental parasites at delivery. Special atten-
tion was paid to the IL-10−1082*A/IL-10−819*T/IL-10−592*A
(IL10-ATA) haplotype carriers, assimilated to low IL-10
producers [60,61]. It emerges from this study that infants
born from IL10-ATA (and IL-10−819 CT and TT) mothers
inherit poorer physiological conditions than others, with a
greater risk of anaemia, possibly in relation to the greater
risk of placenta malarial infection as well as presence of cir-
culating parasites observed in IL-10−1082 AAmothers.
IL-10 is an important immune modulating factor with
anti-inflammatory activities that lead to inhibition of the
activation of antigen-presenting cells, resulting in their
reduced ability to induce T cell responses. But IL-10 hasalso some pro-inflammatory activity since it promotes
activation and differentiation of B cells and induces im-
munoglobulin synthesis [62]. It is therefore expected
that low IL-10 producers such as the IL10-ATA carriers
present lower antibody levels compared to no IL10-ATA
carriers. For example, a previous study showed that the
IL-10−1082*A/IL-10−592*A haplotype was associated with
decreased specific IgE and IgG4 levels [23]. But con-
versely to this expectation, IL-10−1082 AA mothers of the
present study had higher IgG to MSP-2/3D7 than GG
and GA ones. This pattern of response found an im-
munological echo in the newborns, as those born from
mothers with the IL-10−1082 AA genotype presented
higher IgG levels to AMA-1 compared to newborns
from GG and GA mothers. Two hypotheses can be put
forward to explain this observation. Firstly, the lower de-
gree of control of P. falciparum infection in IL-10−1082
AA mothers may result in a strongest antibody response
in both mothers and their newborns (via the in utero
transfer of maternal IgG and/or the production of intrin-
sic IgG in response to parasitic soluble antigens encoun-
tered in utero). Secondly, there is no dogma regarding a
decreased IL-10 production in individuals with IL10-
ATA haplotype, as the combination of a particular IL-1
genotype with the IL10-ATA haplotype was shown to re-
sult in increased IL-10 plasma levels in healthy Finnish
individuals, demonstrating the importance of the indi-
vidual genetic background [63].
Turner et al. demonstrated a difference in IL-10 secre-
tion in association with the presence or absence of of the
IL-10−1082*A allele in the human IL-10 promoter, after
stimulation of peripheral blood mononuclear cells [22].
This is in accordance with our observation of lower IL-10
plasma levels in mothers with the IL-10−1082 GA genotype
compared to those with the GG genotype. Nevertheless,
no difference in the plasma IL-10 levels according to IL-10
haplotypes was recorded in the sub-sample of 80 mothers
for whom cytokine levels were measured. It should be
noted that individual differences in the levels of the IL-10
measured at a specific moment may not only result from
host genetic factors predisposing to high or low produc-
tion, but also for a great part from the physiological condi-
tion at that time, as well as from global immunity.
In Thailand, the functional IL-13−1055*T allele has been
shown to enhance resistance to severe malaria through
the alteration of IL-13 production [16]. The same allele
has been associated with resistance to S. mansoni [64,65]
and inversely with susceptibility to S. haematobium in-
fection [66]. Isnard et al. established that the IL-13−1055
C/T polymorphism is in LD with other polymorphisms
[66], suggesting that only weak effects may be revealed
when investigating the single polymorphism in relation
to clinical or immunological phenotypes. This may ex-
plain why IL-13−1055 C/T alleles were not found
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cept lower IgG levels to AMA-1 in newborns from IL-13
−1055 TT vs. CC and TT mothers. It would be unwise to
comment this observation, as it did not present any bio-
logical corollary (either in mothers or newborns) in the
present study.
Besides the main results, it is interesting to note that the
distribution of the cytokine genotypes in our study popu-
lation from south Benin (most participants belonging to
the Tori ethnic group) is similar to that observed in the
Yoruba (YRI) sample from the 1000 Genomes project
[67], located in the neighboring country (Nigeria), and the
opposite of the one observed in the European (CEU) sam-
ple of the same database (data not shown). This distribu-
tion profile may suggest a selective genetic advantage
conferred by the secular pressure exerted by infectious
diseases such as malaria [68].
Conclusion
This study shows that IL-4 and IL-10 gene polymor-
phisms are likely to play a role in the regulation of
mothers’ and newborns’ control of malaria infection.
This is the first demonstration of an impact of maternal
IL-10 gene polymorphisms on the newborn specific IgG
production, opening hypotheses about the consequences
that this may have later in the life of the child for the
elaboration of his own IgG responses. These results may
provide a contribution to a better understanding of the
immunopathogenic mechanisms underlying maternal-
fetal interactions. Further studies are required to
strengthen the knowledge of the impact of maternal
gene polymorphisms on the immunoglobulin isotypes
synthesized by the fetus and thereafter the infant.
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Additional file 1: Association between maternal cytokine gene
polymorphisms and mothers’ biological parameters (n = 576):
univariate analysis. This table summarizes the results of the univariate
analysis performed for examining differences between maternal cytokine
genotypes or haplotypes and biological parameters (haemoglobin,
prevalence of circulating P. falciparum parasites, prevalence of P.
falciparum placenta infection) of mothers.
Additional file 2: Association between maternal cytokine gene
polymorphisms and newborns’ biological parameters (n = 576):
univariate analysis. This table summarizes the results of the univariate
analysis performed for examining differences between maternal cytokine
genotypes or haplotypes and biological parameters (birthweight,
haemoglobin) of newborns.
Additional file 3: Association between maternal cytokine gene
polymorphisms and mothers’ antibody levels to P. falciparum
antigens (n = 576): univariate analysis. This table summarizes the
results of the univariate analysis performed for examining differences
between maternal cytokine genotypes or haplotypes and mothers’ IgG
levels to 7 recombinant proteins of P. falciparum asexual stage antigens
as well as IgM levels to 1 of these antigens.
Additional file 4: Association between maternal cytokine gene
polymorphisms and newborns’ antibody levels to P. falciparumantigens (n = 576): univariate analysis. This table summarizes the
results of the univariate analysis performed for examining differences
between maternal cytokine genotypes or haplotypes and newborns’ IgG
levels to 7 recombinant proteins of P. falciparum asexual stage antigens
as well as IgM levels to 1 of these antigens.
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